Search results
Results from the WOW.Com Content Network
Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. [4] Central to the physiologic maintenance of GFR is the differential basal tone of the afferent (input) and efferent (output) arterioles (see diagram).
The Glomerular filtration rate (GFR) is regarded as the best overall measure of the kidney's ability to carry out these numerous functions. An estimate of the GFR is used clinically to determine the degree of kidney impairment and to track the progression of the disease. The GFR, however, does not reveal the source of the kidney disease.
A better estimate of kidney function is given by calculating the estimated glomerular filtration rate (eGFR). eGFR can be calculated without a 24-hour urine collection, using serum creatinine concentration and some or all of the following variables: sex, age, and weight, as suggested by the American Diabetes Association. [19]
LabCorp offers testing to detect the presence of albumin in the urine, which helps detect kidney damage beyond that which tends to occur with normal aging, and a serum creatinine test, from which ...
EGFR may refer to: Epidermal growth factor receptor (EGFR), a transmembrane receptor protein in humans; Estimated glomerular filtration rate (eGFR), a measure of ...
In countries that do not use the CHEM-7 panel, a UEC typically does not include chloride or bicarbonate as standard components, but will often include an estimated glomerular filtration rate (eGFR), and in some laboratories, glucose is also not included but is available as a separate test.
The GFR is derived from the serum creatinine and is proportional to 1/creatinine, i.e. it is a reciprocal relationship; the higher the creatinine, the lower the GFR. It reflects one aspect of kidney function, how efficiently the glomeruli – the filtering units – work. The normal GFR is >90 ml/min.
A phase 2 study in EGFR wild-type non-small cell lung cancer is being planned, where Temab-A will be evaluated with a PD-1 inhibitor as a frontline combination therapy.